A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via Convection-Enhanced Delivery In Patients With Progressive And/Or Multiple Recurrent Glioblastoma Multiforme
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
At a glance
- Drugs BMP 4 (Primary) ; BMP 4 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors StemGen
- 03 Oct 2017 Planned End Date changed from 1 Jan 2018 to 11 Sep 2018.
- 03 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 12 Jun 2018.
- 03 Oct 2017 Status changed from not yet recruiting to recruiting.